| Attention‐deficit‐hyperactivity disorder: an update JA Dopheide, SR Pliszka Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29 (6 …, 2009 | 331 | 2009 |
| Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects GL Stimmel, JA Dopheide, SM Stahl Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 17 (1 …, 1997 | 249 | 1997 |
| Recognizing and treating depression in children and adolescents JA Dopheide American journal of health-system pharmacy 63 (3), 233-243, 2006 | 246 | 2006 |
| Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. JA Dopheide The American journal of managed care 26 (4 Suppl), S76-S84, 2020 | 224 | 2020 |
| The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD JA Dopheide Am J Manag Care 15 (5 Suppl), S141-50, 2009 | 41 | 2009 |
| Role of a psychiatric pharmacist in a Los Angeles “Skid-Row” safety-net clinic I Wang, JA Dopheide, P Gregerson Journal of Urban Health 88, 718-723, 2011 | 31 | 2011 |
| ASHP therapeutic position statement on the appropriate use of medications in the treatment of attention-deficit/hyperactivity disorder in pediatric patients JA Dopheide American journal of health-system pharmacy 62 (14), 1502-1509, 2005 | 31 | 2005 |
| Curriculum in psychiatry and neurology for pharmacy programs JA Dopheide, JR Bostwick, LW Goldstone, K Thomas, R Nemire, ... American journal of pharmaceutical education 81 (7), 5925, 2017 | 29 | 2017 |
| Psychotropic drug-induced reductions in seizure threshold: incidence and consequences GL Stimmel, JA Dopheide CNS drugs 5, 37-50, 1996 | 25 | 1996 |
| Childhood disorders JA Dopheide, JT Tesoro, M Malkin Pharmacotherapy: A Pathophysiologic Approach 2008, 1029-1040, 2008 | 22 | 2008 |
| Depression screening in a university campus pharmacy: a pilot project ED Knox, JA Dopheide, MZ Wincor, PK Han Journal of the American Pharmacists Association 46 (4), 502-506, 2006 | 22 | 2006 |
| A naturalistic comparison of adverse effects between slow titration and loading of divalproex sodium in psychiatric inpatients WJ Lima, JA Dopheide, BA Kramer, CA Earhart, MZ Wincor Journal of affective disorders 52 (1-3), 261-267, 1999 | 20 | 1999 |
| Psychiatric pharmacist and primary care collaboration at a skid-row safety-net clinic B Chung, JA Dopheide, P Gregerson Journal of the National Medical Association 103 (7), 567-575, 2011 | 16 | 2011 |
| Positioning psychiatric pharmacists to improve mental health care JA Dopheide, A Werremeyer, RJ Haight, CA Gutierrez, AM Williams Mental Health Clinician 12 (2), 77-85, 2022 | 15 | 2022 |
| Acetylcysteine for treatment of autism spectrum disorder symptoms D Stutzman, J Dopheide American Journal of Health-System Pharmacy 72 (22), 1956-1959, 2015 | 15 | 2015 |
| Antipsychotic selection for acute agitation and time to repeat use in a psychiatric emergency department S Gomez, J Dopheide Journal of Psychiatric Practice® 22 (6), 450-458, 2016 | 13 | 2016 |
| Psychotropic medication use at a private eating disorders treatment facility: A retrospective chart review and descriptive data analysis KN Gable, JA Dopheide Current therapeutic research 66 (6), 572-588, 2005 | 12 | 2005 |
| Focus on nefazodone: A seotonergiiic drug for major depression. JA Dopheide, GL Stimmel Hospital Formulary 30 (4), 205-211, 1995 | 12 | 1995 |
| Collaboration between child and adolescent psychiatrists and mental health pharmacists to improve treatment outcomes DH Lu, JA Dopheide, D Wang, JK Jeffrey, S Chen Child and Adolescent Psychiatric Clinics 30 (4), 797-808, 2021 | 10 | 2021 |
| Sleep disorders JA Dopheide, GL Stimmel Koda-Kimble MA, Young LY, Kradjan WA et al, 1-22, 1995 | 10 | 1995 |
